Home » Stocks » Emerald Bioscience

Emerald Bioscience Inc. (EMBI)

Stock Price: $0.0400 USD -0.0010 (-2.44%)
Updated Aug 7, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 7.33M
Revenue (ttm) n/a
Net Income (ttm) 13.48M
Shares Out 183.21M
EPS (ttm) 0.03
PE Ratio 1.33
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.0400
Previous Close $0.0410
Change ($) -0.0010
Change (%) -2.44%
Day's Open 0.0502
Day's Range 0.0410 - 0.0531
Day's Volume 923,544
52-Week Range 0.0400 - 0.4900

More Stats

Market Cap 7.33M
Enterprise Value 7.28M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 183.21M
Float 52.34M
EPS (basic) 0.11
EPS (diluted) 0.03
FCF / Share -0.03
Dividend n/a
Dividend Yield n/a
Earnings Yield 75.00%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 0.84
PE Ratio 1.33
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 30.09
Revenue n/a
Operating Income -7.33M
Net Income 13.48M
Free Cash Flow -5.86M
Net Cash 50,622
Net Cash / Share 0.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -169.71%
ROE n/a
ROIC -294.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$2.00*
Low
2.00
Current: $0.0400
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue-------0.02
Gross Profit-------0.01
Operating Income-6.63-4.69-3.86-4.47-4.32-2.73-0.12-
Net Income1.05-19.19-3.09-3.18-4.84-2.73-0.12-
Shares Outstanding13512127.9118.9516.9410.297.772.33
Earnings Per Share-0.05-0.16-0.11-0.17-0.29-0.27-0.02-
Operating Cash Flow-6.03-3.94-3.33-3.55-3.73-1.76--
Capital Expenditures---0.02-0.01--0.02--
Free Cash Flow-6.03-3.95-3.35-3.56-3.73-1.78--
Cash & Equivalents1.831.860.260.103.260.210.000.03
Total Debt0.391.360.24-----
Net Cash / Debt1.450.500.030.103.260.210.000.03
Assets2.001.960.560.323.510.35-0.04
Liabilities1.4517.521.361.773.040.800.18-
Book Value0.55-15.56-3.57-2.91-0.89-0.45-0.180.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Emerald Bioscience Inc.
Country United States
Employees 4
CEO Brian Stuart Murphy

Stock Information

Ticker Symbol EMBI
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: EMBI

Description

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111 for the treatment of glaucoma. Its products pipeline also comprise NB2222 for the treatment of dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3000 for the treatment of methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is headquartered in Long Beach, California.